Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments

Frontiers in Endocrinology

Volumn 5, Issue OCT, 2014, Pages

  Sasaki, Akira ^a   Nitta, Hiroyuki ^a   Otsuka, Koki ^a   Umemura, Akira ^a   Baba, Shigeaki ^a   Obuchi, Toru ^a   Wakabayash, Go ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Bariatric surgery; Diabetes; Laparoscopy; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Obesity

Indexed keywords

ADIPONECTIN; BILE ACID; C REACTIVE PROTEIN; CHOLESTEROL; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HIGH DENSITY LIPOPROTEIN; INCRETIN; LEPTIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; DIET; EXERCISE; FIBROSIS; GASTRIC BANDING; HEPATITIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; REVIEW; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; STEATOSIS; STOMACH BYPASS; WEIGHT REDUCTION;

EID: 84919706677     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00164     Document Type: Review

References (61)

1. Patel AA, Torres DM, Harrison SA. Effect of weight loss on nonalcoholic fatty liver disease. J Clin Gastroenterol (2009) 43(10):970-4. doi:10.1097/MCG.0b013e3181b57475
2. Kopelman PG. Obesity as a medical problem. Nature (2000) 404(6778):635-43. doi:10.1038/35007508
3. Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalized treatment based on pathogenic targets. Aliment Pharmacol Ther (2014) 39(1):3-14. doi:10.1111/apt.12543
4. Paredes AH, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Clin Liver Dis (2012) 16(2):397-419. doi:10.1016/j.cld.2012.03.005
5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and managements of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology (2012) 55(6):2005-23. doi:10.1002/hep.25762
6. Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab (2013) 27(2):195-208. doi:10.1016/j.beem.2013.02.002
7. Attar BM, Van Thiel DH. Current concepts and management approaches in nonalcoholic fatty liver disease. ScientificWorldJournal (2013) 2013:481893. doi:10.1155/2013/481893
8. Tanaka N, Horiuchi A, Yokoyama T, Kaneko G, Horigome N, Yamaura T, et al. Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy. J Gastroenterol (2011) 46(6):758-68. doi:10.1007/s00535-011-0370-5
9. Marra F, Lotersztajin S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des (2013) 19(29):5250-69. doi:10.2174/13816128113199990344
10. Franz MJ, VanWormer JJ, Craiin AL, Boucher JL, Histon T, Caplan W, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc (2007) 107(10):1755-67. doi:10.1016/j.jada.2007.07.017
11. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes (2013) 2013:839275. doi:10.1155/2013/839275
12. Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications (2007) 21(3):137-42. doi:10.1016/j.jdiacomp.2007.02.005
13. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis (2010) 28(1):155-61. doi:10.1159/000282080
14. Hussein O, Grosovski M, Schlesinger S, Szvalb S, Assy N. Orlostat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci (2007) 52(10):2512-9. doi:10.1007/s10620-006-9631-1
15. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology (2009) 49(1):80-6. doi:10.1002/hep.22575
16. Drucker DJ. The biology of incretin hormones. Cell Metab (2006) 3(3):153-65. doi:10.1016/j.cmet.2006.01.004
17. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology (2006) 43(1):173-81. doi:10.1002/hep.21006
18. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, et al. Glucagon-like protein-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol (2012) 302(8):G762-72. doi:10.1152/ajpgi.00476.2011
19. Kim YO, Schuppan D. When GLP-1 hits the liver: a novel approach for insulin resistance and NASH. Am J Physiol Gastrointest Liver Physiol (2012) 302(8):G759-61. doi:10.1152/ajpgi.00078.2012
20. Visbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta- analysis of randomized controlled trials. BMJ (2012) 344:d7771. doi:10.1136/bmj.d7771
21. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, AI Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet (2009) 374(9701):1600-16. doi:10.1016/S0140-6736(09)61375-1
22. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effects of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta- analysis. Clin Gastroenterol Hepatol (2008) 6(12):1396-402. doi:10.1016/j.cgh.2008.08.012
23. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Detabase Syst Rev (2010) 20(1):CD007340. doi:10.1002/14651858.CD007340.pub2
24. Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia (2009) 52(11):2270-6. doi:10.1007/s00125-009-1511-8
25. Sasaki A, Wakabayashi G, Yonei Y. Current status of bariatric surgery in Japan and effectiveness in obesity and diabetes. J Gastroenterol (2014) 49(1):57-63. doi:10.1007/s00535-013-0802-5
26. Mells JE, Anania FA. The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis (2013) 33(4):343-57. doi:10.1055/s-0033-1358527
27. Falken Y, Hellstrom PM, Holst JJ, Naslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab (2011) 96(7):2227-35. doi:10.1210/jc.2010-2876
28. Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol (2006) 101(2):368-73. doi:10.1111/j.1572-0241.2006.00419.x
29. Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Häkkinen AM, Tamminen M, et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes (2003) 52(3):701-7. doi:10.2337/diabetes.52.3.701
30. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol (1995) 104(1): 23-31.
31. Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg (2005) 242(4):610-620. doi:10.1097/01.sla.0000179652.07502.3f
32. Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Surg (2005) 13(7):1180-6.
33. Mottin CC, Moretto M, Padoin AV, Kupski C, Swarowsky AM, Glock L, et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg (2005) 15(6):788-93. doi:10.1381/0960892054222830
34. Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L, Feirt N, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology (2006) 130(6):1564-72. doi:10.1053/j.gastro.2006.01.042
35. Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes Surg (2006) 16(5):607-11. doi:10.1381/096089206776944904
36. de Almeida SR, Rocha PR, Sanches MD, Leite VH, da Silva RA, Diniz MT, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg (2006) 16(3):270-8. doi:10.1381/096089206776116462
37. Furuya CK Jr, de Oliveira CP, de Mello ES, Faintuch J, Raskovski A, Matsuda M, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol (2007) 22(4):510-4. doi:10.1111/j.1440-1746.2007.04833.x
38. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg (2007) 17(4):486-92. doi:10.1007/s11695-007-9086-2
39. Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis (2010) 28(1):274-9. doi:10.1159/000282102
40. Meretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC. Effect of bariatric surgery on liver fibrosis. Obes Surg (2012) 22(7):1044-9. doi:10.1007/s11695-011-0559-y
41. Vargas V, Allende H, Lecube A, Salcedo MT, Baena-Fustegueras JA, Frot JM, et al. Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. World J Hepatol (2012) 4(12):382-8. doi:10.4254/wjh.v4.i12.382
42. Tai CM, Huang CK, Hwang JC, Chiang H, Chang CY, Lee CT, et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg (2012) 22(7):1016-21. doi:10.1007/s11695-011-0579-7
43. Himpens J, Dapri G, Cadière GB. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg (2006) 16:1450-6. doi:10.1381/096089206778869933
44. Hutter MM, Schirmer BD, Jones DB, Ko CY, Cohen ME, Merkow RP, et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg (2011) 254(3):410-20. doi:10.1097/SLA.0b013e31822c9dac
45. Buckwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg (2013) 23(4):427-36. doi:10.1007/s11695-012-0864-0
46. Dixon JB, Bhathal PS, Hughes NR, Obrien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology (2004) 39(6):1647-54. doi:10.1002/hep.20251
47. Dixon JB, Bhathal PS, Obrien PE. Weight loss nad non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg (2006) 16(10):1278-86. doi:10.1381/096089206778663805
48. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology (2009) 137(2):532-40. doi:10.1053/j.gastro.2009.04.052
49. Karcz WK, Krawczykowski D, Kuesters S, Marjanovic G, Kulemann B, Grobe H, et al. Influence of sleeve gastrectomy on NASH and type 2 diabetes mellitus. J Obes (2011) 2011:765473. doi:10.1155/2011/765473
50. Umemura A, Sasaki A, Nitta H, Otsuka K, Suto T, Wakabayashi G. Effects of changes in adipocyte hormones and visceral adipose tissue and the reduction of obesity-related comorbidities after laparoscopic sleeve gastrectomy in Japanese patients with severe obesity. Endocr J (2014) 61(4):381-91. doi:10.1507/endocrj. EJ13-0524
51. Keshishian A, Zahriya K, Willes EB. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obes Surg (2005) 15(10):1418-23. doi:10.1381/096089205774859290
52. Kral JG, Thung SN, Brion S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery (2004) 135(1):48-58. doi:10.1016/j.surg.2003.10.003
53. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 114(2):147-52. doi:10.1172/JCI200422422
54. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab (2011) 96(4):1093-7. doi:10.1210/jc.2010-2190
55. Ionut V, Burch M, Youdim A, Bergman RN. Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity (2013) 21(6):1093-103. doi:10.1002/oby.20364
56. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (2009) 17(9):1671-7. doi:10.1038/oby.2009.102
57. Haluzíková D, Lacinová Z, Kaválková P, Drápalová J, Křížová J, Bártlová M, et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity (Silver Spring) (2013) 21(7):1335-42. doi:10.1002/oby.20208
58. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology (2012) 153(8):3613-9. doi:10.1210/en.2011-2145
59. Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart (2012) 98(24):1763-77. doi:10.1136/heartjnl-2012-301778
60. Poirier P, Auclair A. Role of bariatric surgery in diabetes. Curr Cardiol Rep (2014) 16(2):444. doi:10.1007/s11886-013-0444-5
61. Laferrere B. Diabetes remission after bariatric surgery: is it just the incretins? Int J Obes (Lond) (2011) 35(Suppl 3):S22-5. doi:10.1038/ijo.2011.143